The BOLERO-2 trial showed substantial improvements in PFS with the combination of everolimus and exemestane, compared with exemestane alone, in patients with advanced HR-positive breast cancer who had progressed on nonsteroidal aromatase inhibitors.11 Despite these improvements in PFS, resistance to the combination of everolimus and exemestane can occur. The gene discussed is CYP19A1; the disease is breast cancer.